OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Hyperglycemia in diabetes
High blood sugar (hyperglycemia) affects people who have diabetes. Several factors can contribute to hyperglycemia in people with diabetes, including food and physical activity choices, illness, nondiabetes medications, or skipping or not taking enough glucose-lowering medication.
Disease Symptoms
Early signs and manifestations: Recognizing early side effects of hyperglycemia can offer you some assistance with treating the condition immediately. Look for: Frequent pee, Increased thirst, Blurred vision, Fatigue, Headache. Later signs and indications: If hyperglycemia goes untreated, it can bring about harmful acids (ketones) to develop in your blood and pee (ketoacidosis). Signs and manifestations include: Fruity-noticing inhale, Nausea and heaving, Shortness of inhale, Dry mouth, Weakness, Confusion, Coma, Abdominal torment.
Disease Treatment
Get physical. Regular exercise is often an effective way to control your blood sugar. However, don't exercise if ketones are present in your urine. This can drive your blood sugar even higher. Take your medication as directed. If you have frequent episodes of hyperglycemia, your doctor may adjust the dosage or timing of your medication. Follow your diabetes eating plan. It helps to eat less and avoid sugary beverages. If you're having trouble sticking to your meal plan, ask your doctor or dietitian for help.
Statistics
There is a graded rise in cardiovascular risk with increasing hyperglycemia in patients with overt diabetes. In fact, as demonstrated by a meta-analysis of 13 prospective cohort studies, for every one-percentage point increase in glycosylated hemoglobin (HbA1c), the relative risk for any cardiovascular event was 1.18 (95% CI 1.10–1.26).In the ACCORD study, 10,250 patients with long-standing type 2 diabetes were randomly assigned to either intensive or standard glycemic control. After a median followup of 3.7 years, intensive therapy was discontinued due to a higher number of total and cardiovascular deaths in subjects assigned to intensive therapy (median HbA1C 6.4 percent) compared with the standard treatment group (median HbA1C 7.5 percent)
